Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02385877 · ClinicalTrials.gov registry record · Early Phase 1
Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines
A Early Phase 1 study of Autonomic Peripheral Nervous System Diseases, sponsored by University of Michigan.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02385877 is a Early Phase 1 study of Autonomic Peripheral Nervous System Diseases that has completed, run by University of Michigan. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02385877, a Early Phase 1 study of Autonomic Peripheral Nervous System Diseases, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to perform first-in-human PET imaging studies of two new cardiac sympathetic nerve imaging agents, 4-\[18F\]fluoro-meta-hydroxyphenethylguanidine (\[18F\]4F-MHPG) and 3-\[18F\]fluoro-para-hydroxyphenethylguanidine (\[18F\]3F-PHPG).
Conditions Studied
Interventions
- DRUG [18F]4F-MHPG
- DRUG [18F]3F-PHPG
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02385877
The ClinicalTrials.gov registry entry for NCT02385877 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autonomic Peripheral Nervous System Diseases appearing as the primary indexed condition, and to 2 interventions - of which [18F]4F-MHPG is the first listed.
NCT02385877 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02385877 about?
NCT02385877 is a clinical study titled "Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines". The purpose of this study is to perform first-in-human PET imaging studies of two new cardiac sympathetic nerve imaging agents, 4-\[18F\]fluoro-meta-hydroxyphenethylguanidine (\[18F\]4F-MHPG) and 3-\[18F\]fluoro-para-hydroxyphenethylguanidine (\[18F\]3F-PHPG).
What is the current status of trial NCT02385877?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2015-03. Estimated completion is 2016-08.
What conditions does trial NCT02385877 study?
This clinical trial studies the following conditions: Autonomic Peripheral Nervous System Diseases.
What interventions are being tested in trial NCT02385877?
The interventions under investigation include: [18F]4F-MHPG (DRUG), [18F]3F-PHPG (DRUG).
Who is sponsoring clinical trial NCT02385877?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02385877 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.